Early viral kinetics: a novel guide for optimal dosing frequency of pegylated interferon-α-2a in HIV/HCV-coinfected patients

References

• Murphy AA, Herrmann E, Osinusi AO et al. Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. AIDS25, 1179–1187 (2011).
   PubMedGoogle Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med.351, 438–450 (2004).
   PubMed Web of Science ®Google Scholar
• Rozenberg L, Haagmans BL, Neumann AU et al. Therapeutic response to peg-IFN-α-2b and ribavirin in HIV/HCV co-infected African–American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS23, 2439–2450 (2009).
   PubMedGoogle Scholar
• Dahari H, Affonso de Araujo ES, Haagmans BL et al. Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J. Hepatol.53(3), 460–467 (2010).
   PubMedGoogle Scholar
• Van den Eynde E, Crespo M, Esteban JI et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin. Infect. Dis.48(8), 1152–1159 (2009).
   PubMed Web of Science ®Google Scholar
• Dahari H, Layden-Almer JE, Perelson AS, Layden TJ. Hepatitis C viral kinetics in special populations. Curr. Hepat. Rep.7(3), 97–105 (2008).
   PubMedGoogle Scholar
• Laguno M, Larrousse M, Murillas J et al. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. J. Acquir. Immune Defic. Syndr.44(2), 174–178 (2007).
   PubMedGoogle Scholar
• Laufer N, Bolcic N, Rolon MJ et al. HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin. Antivir. Res.90(1), 92–97 (2011).
   PubMedGoogle Scholar
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection. European Association for the Study of the Liver. J. Hepatol.55, 245–264 (2011).
   PubMed Web of Science ®Google Scholar
• Bruno R, Sacchi P, Ciappina V et al. Viral dynamics and pharmacokinetics of peginterferon α-2a and peginterferon α-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir. Ther.9(4), 491–497 (2004).
   PubMed Web of Science ®Google Scholar
• Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology24(4), 778–789 (1996).
   PubMed Web of Science ®Google Scholar
• Roberts SK, Weltman MD, Crawford DH et al. Impact of high-dose peginterferon α-2a on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology50, 1045–1055 (2009).
   PubMed Web of Science ®Google Scholar
• Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-α-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J. Viral. Hepat.10(4), 271–276 (2003).
   PubMed Web of Science ®Google Scholar
• Lurie Y, Rouzier-Panis R, Webster GJ et al. Optimal dosing frequency of pegylated interferon α-2b monotherapy for chronic hepatitis C virus infection. Clin. Gastroenterol. Hepatol.3(6), 610–615 (2005).
   PubMed Web of Science ®Google Scholar
• Sebastiani G, Ferrari A, Boccato S, Pistis R, Alberti A. Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon α 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C. Aliment. Pharmacol. Ther.26(7), 1077–1082 (2007).
   PubMedGoogle Scholar
• Silva M, Poo J, Wagner F et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon α-2b and peginterferon α-2a in patients with chronic hepatitis C (COMPARE). J. Hepatol.45, 204–213 (2006).
   PubMed Web of Science ®Google Scholar
• de Araujo ES, Dahari H, Cotler SJ et al. Pharmacodynamics of PEG-IFN-[α]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. J. Acquir. Immune Defic. Syndr.56(2), 95–99 (2011).
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med.364, 2405–2416 (2011).
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon α-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet376, 705–716 (2010).
   PubMed Web of Science ®Google Scholar